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Step therapy is a cost-saving measure employed by insurance companies to
reduce rising drug costs; however, studies have indicated this policy has neutral
or negative effects on patients. Specifically, for individuals with autoimmune
diseases, the delay of proper treatment, increased risk of negative, and an
underdeveloped preferred drug lists harm autoimmune patients because of the
disconnect between the heterogeneity of autoimmune disease and the one-sizefits-all approach of step therapy. The objective of this study is to determine the
most effective policy for dealing with the harms of step therapy in Florida. Five
policy options were evaluated on a ten-point scale with respect to feasibility,
benefits to insurance companies, to patients, and to physicians. Complete
Reform had the highest comparative advantage. Complete Reform includes
clinical review reform, transparency and reporting requirements, exemptions
criteria, and a streamlined appeals process. It will increase patients’ access to
appropriate, doctor-prescribed medication in a timely manner dramatically
increasing health while preserving physician autonomy and protecting
insurance companies’ revenues.

Background | Healthcare costs in the United States
have steadily increased, growing 8.6% from 2017 to
2019.1 Prescription drug spending has also been rising,
5.8% from 2017 to 2019.2 Strikingly, but also
predictably, healthcare costs per person have increased
233% from 2000 to 2019.1 The US now spends
$11,587 per person on healthcare and 10% of those
costs are attributed to prescriptions.1,2 More
poignantly, prescription costs per person have
increased 272% since 2000 and do not appear to be
slowing.2
To combat high medical costs and provide low
premiums for customers insurance companies
introduced many cost-saving measures.3-5 Such
measures serve to decrease drug costs by diverting
patients towards cheaper, older, or generic drugs first,
before covering more expensive treatments.6-8 Step
Therapy is one of those: insurance companies create
Preferred Drug Lists (PDL’s) and categorize various
drugs into a tiered system: the higher the tier, the less
likely the insurance company will cover the drug.9,10
They require patients “to fail” on “first-line
treatments” before trying “second-line (or higher)
treatments,” even if the physician initially prescribed
higher tier drugs.11-13 Under the Affordable Care Act,
all insurance companies’ PDL’s are required to cover

at least one drug from each pharmacology category
and class.14
Insurance companies follow a two-pronged method in
determining the content of the PDL’s. On one hand, a
small group of physicians and pharmacists determine
whether drugs are effective treatments for
conditions.15 On the other hand, pharmaceutical
companies offer financial incentives to entice
insurance companies to prioritize their brand-name
drug over similar drugs. The bargaining for priority
placement on PDL’s occurs annually leading to
different drugs being considered “the preferred brandname treatment” for specific illnesses.7,16 Thus, PDL’s
shift in response to financial and medical decisions.
Traditionally, PDL’s are broken into four tiers: generic
drugs, preferred brand-name drugs, non-preferred
brand-name drugs, and preferred specialty drugs.17,18
It is important to note for generic drugs, normally the
“first-line treatment,” that while the active ingredients
are the same, inactive ingredients (e.g. dyes, capsules,
etc.) differ and can have varied effects on patients.19,20
Autoimmune diseases are chronic medical conditions
caused by the body’s immune system targeting organs
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in the body.21 The body mounts immune responses
resulting in inflammation, fatigue, or fevers as well as
more dire conditions like glandular disorders.22 The
American Autoimmune and Related Disease
Association has identified over 100 different diseases,
examples being Rheumatoid Arthritis, Psoriatic
Arthritis, and Crohn’s Disease.21 Roughly 23.5 million
Americans suffer from autoimmune diseases and the
rates of autoimmunity are rising.23 Due to the variable
immune responses in individuals, autoimmune
diseases are classified as heterogeneous where each
disease can present itself differently between
patients.6,24
The one-size-fits-all nature of step therapy clashes
with the individuality of autoimmune disease
treatment; this problem also harms the general public.
Despite promises of low premiums, delays in
treatments, stress of the appeals process, and
diminished patient-physicians relationships plague
step therapy. 40% of patients exposed to step therapy
stopped medication because it felt unhelpful and 36%
of patients felt a decline in quality of life.25 Among
arthritis patients, 50% tried at least two drugs before
reaching the prescribed one. 20% stated their
condition worsened as a result of the other
treatments.26 Physicians lose medical autonomy and
patient care time dealing with step therapy and the
administrative process.27,28 On top of these problems,
research indicates that even when prescription costs
are saved, greater medical costs arise from future
medical services.3,4,29,30
There are FOUR problematic areas.3,5,8,11,12,28,31
1. Clinical Review Committee. Clinical review
committee (CRC) reform is necessary to ensure
patients are receiving state-of-the-art care. Currently,
CRCs consist of a small number of specialists and
pharmacists tasked by an insurance company (or third
party) to analyze medical data to determine whether a
drug is adept for treating specific ailments.15,32 The
problem is the small number of members can result in
a lack of expertise across fields.8 Moreover, with 100
different autoimmune diseases, the review committee
cannot be fully knowledgeable about all, therefore it is
highly likely some treatments could be outdated or
ineffective. One study found 78% of physicians
believed there was “poor underlying logic for the
recommended choice” on PDL’s.27
2. Reporting Criteria & Transparency.
Transparency and clear reporting requirements for
insurance companies serve to increase patient and
provider knowledge about step therapy requirements
and new information.3 One study found 40% of
patients stopped medication because of a non-medical

drug switch – a change incentivized not by medical
advice.28 It is necessary ALL patients, regardless of
education, understand their coverage as complicated
language can negatively impact health.28 Furthermore,
transparency allows physicians to proactively
prescribed covered medications and reduce
complications.3 Finally, some insurance companies do
not give a rationale for appeal denial, leaving room for
cost-saving, arbitrary denials.5
3. Exemptions Criteria. Exemption criteria provide
situations for individuals to circumvent step therapy
when medically appropriate based on patients’ history.
There are two factors when dealing with exemption
criteria: the first, patient medical history, and the
second, a clear definition of failure.5,12 Having an
inflexible process eliminates physician’s autonomy in
treating patients’ unique symptoms.8 Cross apply the
inflexibility to the various symptoms of autoimmunity
and step therapy stands to harm autoimmune patients
more. A study of Crohn’s patients found insurance
companies pay 37% more in medical costs when
subjecting them to step therapy because of additional
medical costs due to treatment delays.30 Lack of
exemptions may save short term costs, but total
medical costs actually increase overall health
costs.4,6,8,28-30 Finally, a clear definition of failure
allows for decreased time on harmful drugs.3,5
4. Streamlined Appeals Process. A streamlined
appeals process is necessary to combat long appeal
return times and large amounts of administrative
paperwork. One study found healthcare administrators
spend 50% of their time navigating medical appeals.8
Pharmacists indicate they spend at least 20% (and up
to 80%) of their time managing denied medications.25
Another study found physicians themselves spend
20.4 hours a week dealing with step therapy appeals.28
For patients, one study showed 20% spent >3 hours
resolving a step therapy issue.33 Finally, 59% of
physicians experienced “long delays in processing
decisions or exemptions” often, thus decreasing their
ability to treat patients effectively.27
Methods | A policy matrix was constructed to perform
a relative comparative analysis of the projected policy
benefits on a ten-point scale derived from their
capacity to resolve the problems outlined. Each of the
four criteria evaluations were averaged for a total
comparative advantage of each policy with higher
scores indicating a stronger policy option.
Evaluation Criteria:
1. Feasibility. This value considers the financial and
enforcement resources required to enact policies. It
considers the ability for the policy to pass by analyzing
previous Florida bills.
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2. Benefits to Insurance Company. This value
considers the positive and negative impacts to the
insurance company.
3. Benefits to Patients. This value considers the
positive and negative impacts to patients.
4. Benefits to Physicians. This value considers the
positive and negative impacts to physicians.
It is necessary to describe the omission of pharmacists
and pharmaceutical drugs manufacturing companies.
Pharmacists only involve the distribution of
medication to patients and have little control
prescription choices or costs. Drug manufacturing
companies have little involvement in the prescription
or the actual patient cost for medication as the
insurance company is responsible for the medication
coverage. However, insurance companies might see it
in their interest, as a result, to demand cheaper drug
prices, but consideration of drug prices is outside the
analysis’s scope.
Policy Options:
Policy 1: Insurance Directed Reform. Clinical Review
Committee Reform requires an independent
committee to make evidence-based decisions on
medication coverage with the ability to address all
areas of specialty with a transparent decision-making
process. Furthermore, they will acknowledge the
variations between autoimmune diseases and in their
treatments.
Reporting Requirements require insurance companies
to make their step therapy information accessible to all
levels of education and languages, both patients and
physicians. Furthermore, patients must be
preemptively notified of changes occurring in
medication or coverage with the understanding of why
the change occurred.
Policy 2: Patient Directed Reform. A streamlined
appeal process requires an enforced time frame for
appeal responses with the typical time frame being 24
hours for emergencies and 72 hours for nonemergencies. Moreover, the appeals process will be
simplified with available formats on insurance
company websites with a clear list of possible
exemptions.
Exemption criteria require specific universal
exemptions from step therapy: including medication
already shown to be ineffective, physician believes
drug will be ineffective or harmful based on medical
history, a specified timeframe for “failure” (normally

6-week period), and protections from non-medical
switching.
Policy 3: Complete Reform. Policy 1 + Policy 2
Policy 4: Insurance Directed Reform for
Autoimmune. Policy 1 only for individuals with
autoimmune diseases
Policy 5: Patient Directed Reform for Autoimmune.
Policy 2 only for individuals with autoimmune
diseases
Results | Policy 1: Insurance Directed Reform.
Feasibility: Government involvement in private
business will cause dissent; however, this policy
maintains one overhaul on the insurance side with
minor timely updates. The CRC reform would require
a one-time reworking accompanied by smaller
financial and physical inputs in subsequent years. The
reporting criteria would also be a one-time update on
the website and information dispersal services.
However, bills containing these reforms previously
failed, including SB#1290 (2021), HB#1001 (2021),
SB#906 (2019), HB#559 (2019), SB#98 (2018), HB#
963 (2016). Score-4
Benefits to Insurance Companies: Contracting an
independent CRC requires increased spending and
takes autonomy from insurance companies.
Additionally, an improved CRC would increase the
quantity of covered medications, thus insurance
companies could pay for more medications. However,
more expansive lists could reduce appeals and
patients’ negative symptoms, thus less doctor visits
and decreased future medical bills. The reporting
criteria can increase patient and physician knowledge
and increase efficiency during the appeals process.
Finally, clear rationale for a denial could cause the
insurance company to cover more drugs. Score-4
Benefits to Patients: The patient would have
medications backed by evidence-based, independent
decisions; therefore, treatment options would most
likely increase health. Additionally, understanding of
the appeals process would decrease stress even though
unresolved long return times lead stress and increase
medication discontinuation. In the instance when they
cannot appeal, they required to follow step therapy
protocol and could suffer negative symptoms or
permanent harm. Score-6
Benefits to Physicians: Physicians still lack autonomy
in prescribing, despite a more adept PDL.
Furthermore, despite the information on the website,
the appeals process would require high levels of
administrative burden, reducing patient time. They
KIRKLEY & TATARI

Published by UNF Digital Commons, 2022

3
3

Florida Public Health Review, Vol. 19 [2022], Art. 1

would better understand the insurance plan coverage
and can avoid clashes to streamline the process, but
they would be unable to effectively individualize
treatment. With better patient outcomes, the patientphysician relationship could improve. Score-4
Policy 2: Patient Directed Reform.
Feasibility:
Government
involvement
would
experience stronger pushback because they require
more overreach increasing outcry. They would require
constant monitorization to enforce streamlined appeals
processes and exemption criteria. Florida has
previously dismissed bills containing these reforms,
including SB#1290 (2021), HB#1001 (2021), SB#906
(2019), HB#559 (2019), SB#98 (2018), HB#199
(2018), SB#1084 (2016), HB#963 (2016). Score-3
Benefits to Insurance Companies: A streamlined
appeals process and exemption criteria requires more
staff and increased efficiency for the appeals process.
The government involvement reduces their autonomy,
but they still control PDL’s. With exemptions, the
insurance company would pay for more expensive
medications. While it would cost more for
prescriptions, more appropriate medication promotes
a healthier population resulting in less doctor visits
and decreased down-the-line medical expenses.
However, in the short run, cost would increase which
might raise premiums and decrease customers, but if
applied universally, all insurance companies would
need to raise premiums, thus the patient would not be
incentivized to leave. Score-2
Benefits to Patients: The exemption criteria and
streamlined appeals process would give patients
increased access to appropriate medication in a timely
manner, preventing unnecessary health issues. A
simplified appeals process would reduce stress, but
without the easily accessible information, there still is
stress. The patient-physician relationship would
improve. More appropriate medication would reduce
doctor visits, thus less time and money. Score-8
Benefits to Physicians: Streamlined appeals and
exemption criteria increase physician autonomy in
tailoring treatments and they gain back administrative
time that could be for patients, improving patientphysician relationships. Without clear reporting
criteria, each patient’s coverage plan might complicate
the situation. There might be a drop in doctor visits,
but this is a double-edged sword as people are
healthier, but physicians make less money. Score-9
Policy 3: Complete Reform.
Feasibility: When combining the challenge of passing
the previous two policies, this would be difficult to

pass as it would impose the most oversite for insurance
companies. However, similar bills in other states have
passed, but never in Florida. Score-2
Benefits to Insurance Companies: This is the most
restrictive policy for their autonomy. However, as
shown, step therapy can increase other costs, therefore
they may save money in the long run. They would
have to cover more drugs and improve their appeals
process and information dissemination systems. The
costs are the combined version of Policy 1 and Policy
2. Score-1
Benefits to Patients: While still subject to step therapy,
the patient has the most control over their treatment
and would have leeway if the “first-line treatment” is
harmful or ineffective. They would have the combined
benefits from Policy 1 and Policy 2. The patient
understands step therapy and has a quicker appeals
process which decreases stress and promotes health.
With more knowledge and autonomy, the patient fairs
the best. Score-10
Benefits to Physicians: Physicians gain the most
autonomy and understanding of step therapy and better
patient-physician relationships. Additionally, the
administrative burden is greatly alleviated. Despite the
presence of step therapy, in important instances, it
does not stand in the way. Finally, they have healthier
patients. Score-9.5
Policy 4: Insurance Directed Reform only for
Autoimmune.
Feasibility: The removal of the general public from the
reform makes it more manageable for the insurance
company. However, pushback from non-autoimmune
advocacy groups introduces new conflict. Laws have
never been attempted that separate the public. Finally,
defining autoimmune diseases is difficult because of
its heterogeneity. Score-4
Benefits to Insurance Companies: Supposedly, it
would reduce insurance company stress; however, the
ability to separate a clinical review committee and
reporting criteria solely for autoimmune diseases is
challenging. With autoimmune specialists added to the
review committee, it would increase likelihood of
benefits; however, no individual is an expert in 100
autoimmune diseases. Additionally, it would be
pragmatically facetious to only use independent,
evidence-based decision-making processes only for
autoimmunity. Score-5
Benefits to Patients: Autoimmune patients would
experience the same benefits as Policy 1 and the
general public would receive none. Therefore,
becoming diagnosed as autoimmune to gain special
KIRKLEY & TATARI
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coverages would be important for adequate care of
gray-area patients, thereby increasing stress and
decreasing health. Score-4
Benefits to Physicians: Physicians dealing with
autoimmune patients would receive benefits of Policy
1 and others would experience no change.
Additionally, the moral dilemma of misdiagnosing
autoimmunity to grant patients special coverage
introduces new stress. Score-4
Policy 5: Patient Directed Reform only for
Autoimmune.
Feasibility: With the same changes as Policy 2, but
only for autoimmunity, it would be easier for
insurance companies to follow as well as for the
government to enforce. The challenge of legally
defining autoimmune diseases as well as pushback
from insurance companies and general public reformer
decrease the feasibility. Score-3.5
Benefits to Insurance Companies: Singling out
autoimmunity is more manageable because each
patient could be tagged with an “autoimmunity” label
granting decreased appeal time and exemptions and
would be less overhaul than Policy 2. However,
specialty drugs are 1% of prescriptions, but 25% of the
costs, thus the savings may be less than anticipated.7
Finally, they lose autonomy. Score-5
Benefits to Patients: Autoimmune individuals would
experience the same benefits as Policy 2 and the
general public would not. Pressure would increase to
be diagnosed with autoimmunity for prescriptions.
The heterogeneity of autoimmunity makes diagnosis
difficult for people in-between. Score-5

Benefits to Physicians: Physicians dealing with
autoimmunity would experience the benefits as Policy
2, but general physicians would not. The pressure to
diagnose with autoimmunity for a streamlined appeals
process and exemption criteria would create moral
stress. Score-4
Discussion | Based on analysis of the policies, the
most favorable policy is POLICY #3 (Complete
Reform) (Table 1). It includes Clinical Review
Committee Reform, Reporting Criteria/Transparency,
Exemption Criteria, and Streamlined Appeals Process.
It benefits the patients – including those with
autoimmune conditions – and physicians while
allowing insurance companies to save costs in the long
run.
Limitations | The limitations of the policy analysis
appear in the limited number of policies and limited
number of criteria as it is impossible to consider every
criterion; however, the choices were made to
encompass the maximum amount of information.
Furthermore, the scoring of each value was derived
from relative comparative analysis; however, the
analysis was grounded in evidence from current
programs and issues.
Implications for Public Health Practice | Thus, the
comparatively better policy for individuals with
autoimmune diseases in Florida is POLICY #3
(Complete Reform) to increase all patients’ access to
appropriate, doctor-prescribed medication in a timely
manner dramatically increasing health while
preserving physician autonomy and protecting
insurance companies’ revenue.

Table 1. Policy matrix for evaluating possible policies to address the step therapy impacts on Floridians.

Feasibility

Policy 1:
Insurance
Company
Directed Reform

Policy 2:
Patient
Directed
Reform

Policy 3:
Complete
Reform

- one time overhaul
with subsequent
minor maintenance
for IC
- strong opposition
to past bills
score: 4

- continual
maintenance for
IC
- more
government
involvement for
enforcement
- strong IC
pushback

- combines both
the challenges
of policy 1 & 2
- requires
government
oversite
- bills
containing all
four have died
in the past
score: 2

Policy 4:
(Autoimmune only)
Insurance
Company Directed
Reform
- more manageable
for IC
- regulation on part
of autoimmune
diseases
- laws like this have
never been
introduced before
- difficult to separate
and target
autoimmune

Policy 5:
(Autoimmune only)
Patient Directed
Reform
- more manageable
for IC
- easier than Policy 4
to target and separate
autoimmune
- bills exclusive for
autoimmune never
been introduced
before
- in-between doing
too much on IC side
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- stronger
opposition for
past bills
score: 3

Benefits to
Insurance
Companies

- increased
spending
- increased
government
oversite
-increased coverage
for medications for
all ailments
- less appeals
- need rationale for
denial
-relatively less
involved reform
score: 4

Benefits to
Consumers

- more adept
treatments from
PDL’s
- understand
appeals process and
step therapy policy
and changes
- less stress
- must follow step
therapy
- slow appeals
process
score: 6

Benefits to
Physicians

- loss of autonomy
- better patient
outcomes
- slow appeals
process
- large amount of
time filling out
appeals
- understand
coverage of
patients more
clearly
score: 6

- more
autonomy
- tailored
treatment plans
- decreased
administrative
burden
- lack of
knowledge of
patients’ policies
details
score: 9

4.5

5.5

AVERAGE

- increased
workload
- less autonomy
- increase costs
- still regulate
prescription
choices
- healthier
populations, less
later expenses
- reduced doctor
visits
- pay third party
for CRC
score: 2
- physician
prescribed
treatment in
timely manner
- decreased
health harms
- less time on
failing drugs
- better patientphysician
relationship
- less doctor
visits
- increased
premiums
score: 8

- greater loss of
autonomy
- increased costs
- increased
workload
- increased
government
oversite
- reduced doctor
visits
- healthier
populations
- less future
medical costs
score: 1
- still subject to
step therapy
- more adept
treatments
- understanding
of step therapy
and changes
- quick appeals
process
- decreased
health risks
- less time on
failing drugs
- increased
premiums
- better patientphysician
relationship
- less doctor
visits
score: 10
- most
autonomy
- increased
understanding
of step therapy
- better patient
outcomes
- less
administrative
burden
-better patientphysician
relationship
score: 9.5
5.625

- hard to establish
bright lines
score: 4

and not enough for
step therapy
advocates
score: 3.5

- difficult to
physically dissociate
the benefits of CRCR
& RC without
benefiting the
general public
- require updating
classification system
- pay third party for
CRC on autoimmune
-lose some autonomy
-increased costs
-increased workload
score: 5

- more simplistic to
single out
autoimmune patients
- specialty drugs
make up 25% of
budget for only 1%
of drugs, thus may
not reduce as much
as thought
- lose some
autonomy
score: 5

- definitive
autoimmune patients
would receive same
benefits as Policy 1
- general public
would receive no
benefits
- place increased
burden on being
autoimmune
diagnosis
- hurt general
population that needs
specialty drugs
- diagnosis would
become high in
demand
score: 4

-separate
autoimmune from
general public
- autoimmune
individuals would
experience same
benefit as described
in Policy 2
- general public
would feel no
benefits
- increased burden
and stress on
achieving an
autoimmunity
diagnosis
score: 5

- autoimmune
physicians same as
Policy 1
- general physicians
no change
- increased pressure
from physicians to
diagnose
autoimmune disease
to given better health
coverage
- lengthy appeals
process
score: 4
4.25

- autoimmune
physicians same as
Policy 2
- moral dilemma of
diagnosing
autoimmune for
coverage
- increased stress
- lack of clear
understanding of step
therapy protocol for
patients
score: 4
4.375
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